radionuclides

BQ7859 is a probe designed to target PSMA, equipped with a NOTA chelator, offering exceptional imaging capabilities. It can be labeled with various radionuclides such as [68Ga], [18F], [55Co], and [111In]. In mouse prostate cancer xenograft models, BQ7859 (labeled with [111In]) effectively accumulates in tumor regions through a PSMA-dependent mechanism, providing high-contrast tumor imaging. This compound holds promise for research in prostate cancer imaging, particularly in the areas of positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Additionally, BQ7859 can be used in the synthesis or study of radionuclide conjugate drugs (RDC).

BQ7876 is a probe that targets prostate-specific membrane antigen (PSMA) and contains a DOTA chelator. After radiolabeling with radionuclides (177Lu), BQ7876 specifically binds to PSMA, serving both in radionuclide imaging and tumor cell destruction. It shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC). BQ7876 can also be utilized in the synthesis research of radionuclide conjugated drugs (RDC).